SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CH
obligations may continue. See	
Instruction 1(b).	Filed pursuant to S

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			••••••••••••••••••••••••••••••••••••••						
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Krystal Biotech, Inc. [KRYS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Krishnan Krish S</u>			<u></u>	X Director X 10% Owner					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	X Officer (give title Other (specify below)					
C/O KRYSTAL BIOTECH, INC.			04/17/2023	President and CEO					
2100 WHAR	TON STREET,	SUITE 701							
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
PITTSBURG	н ра	15203		X Form filed by One Reporting Person					
		10200		Form filed by More than One Reporting Person					
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) (Instr.			d (A) or r. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)	(1150.4)	(11150.4)	
Common Stock	04/17/2023		S ⁽¹⁾		1,050	D	\$85.5483(2)	1,733,288	D		
Common Stock	04/17/2023		S ⁽¹⁾		4,298	D	\$86.7964 ⁽³⁾	1,728,990	D		
Common Stock	04/17/2023		S ⁽¹⁾		9,428	D	\$ 87.4113 ⁽⁴⁾	1,719,562	D		
Common Stock	04/17/2023		S ⁽¹⁾		9,724	D	\$88.4062(5)	1,709,838	D		
Common Stock	04/17/2023		S ⁽¹⁾		500	D	\$89.1175(6)	1,709,338	D		
Common Stock	04/17/2023		S ⁽⁷⁾		1,050 ⁽⁸⁾	D	\$85.5487(2)	1,676,213	Ι	By Spouse ⁽⁹⁾	
Common Stock	04/17/2023		S ⁽⁷⁾		4,297 ⁽⁸⁾	D	\$86.7964 ⁽³⁾	1,671,916	I	By Spouse ⁽⁹⁾	
Common Stock	04/17/2023		S ⁽⁷⁾		9,429 ⁽⁸⁾	D	\$ 87.4114 ⁽⁴⁾	1,662,487	I	By Spouse ⁽⁹⁾	
Common Stock	04/17/2023		S ⁽⁷⁾		9,724 ⁽⁸⁾	D	\$88.4062(5)	1,652,763	I	By Spouse ⁽⁹⁾	
Common Stock	04/17/2023		S ⁽⁷⁾		500 ⁽⁸⁾	D	\$89.1175 ⁽⁶⁾	1,652,263	I	By Spouse ⁽⁹⁾	
Common Stock								90,000	I	By Krishnan Spousal Trust	
Common Stock								50,000	I	By Krishnan Family Trust ⁽¹⁰⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Secu Acqu (A) o Dispo of (D	vative rities lired r osed) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of \$80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.

2. The transaction was executed in multiple trades ranging from \$85.0500 to \$86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 3. The transaction was executed in multiple trades ranging from \$86.0500 to \$87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 4. The transaction was executed in multiple trades ranging from \$87.0500 to \$88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 5. The transaction was executed in multiple trades ranging from \$88.0500 to \$89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 6. The transaction was executed in multiple trades ranging from \$89.0650 to \$89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. 7. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of \$80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan.

8. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma Krishnan.

9. Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.

10. Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. **Remarks:**

/s/ Krish S. Krishnan

04/18/2023 Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.